This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Vitamin E and memantine in Alzheimer’s disease: clinical trial methods and baseline data


Dysken, Maurice W., Guarino, Peter D., Vertrees, Julia E., Asthana, Sanjay, Sano, Mary, Llorente, Maria, Pallaki, Muralidhar, Love, Susan, Schellenberg, Gerard D., McCarten, J. Riley, Malphurs, Julie, Prieto, Susana, Chen, Peijun, Loreck, David J., Carney, Sara, Trapp, George, Bakshi, Rajbir S., Mintzer, Jacobo E., Heidebrink, Judith L., Vidal-Cardona, Ana, Arroyo, Lillian M., Cruz, Angel R., Kowall, Neil W., Chopra, Mohit P., Craft, Suzanne, Thielke, Stephen, Turvey, Carolyn L., Woodman, Catherine, Monnell, Kimberly A., Gordon, Kimberly, Tomaska, Julie, Vatassery, Govind


Alzheimer's & Dementia: The Journal Of The Alzheimer's Association, Volume: 10, No.: 1, Pages.: 36-44

Year of Publication



Background: Alzheimer’s disease (AD) has been associated with both oxidative stress and excessive glutamate activity. A clinical trial was designed to compare the effectiveness of (i) alpha-tocopherol, a vitamin E antioxidant; (ii) memantine (Namenda), an N-methyl-D-aspartate antagonist; (iii) their combination; and (iv) placebo in delaying clinical progression in AD.; Methods: The Veterans Affairs Cooperative Studies Program initiated a multicenter, randomized, double-blind, placebo-controlled trial in August 2007, with enrollment through March 2012 and follow-up continuing through September 2012. Participants with mild-to-moderate AD who were taking an acetylcholinesterase inhibitor were assigned randomly to 2000 IU/day of alpha-tocopherol, 20 mg/day memantine, 2000 IU/day alpha-tocopherol plus 20 mg/day memantine, or placebo. The primary outcome for the study is the Alzheimer’s Disease Cooperative Study/Activities of Daily Living Inventory. Secondary outcome measures include the Mini-Mental State Examination; the Alzheimer’s Disease Assessment Scale, cognitive portion; the Dependence Scale; the Neuropsychiatric Inventory; and the Caregiver Activity Survey. Patient follow-up ranged from 6 months to 4 years.; Results: A total of 613 participants were randomized. The majority of the patients were male (97%) and white (86%), with a mean age of 79 years. The mean Alzheimer’s Disease Cooperative Study/Activities of Daily Living Inventory score at entry was 57 and the mean Mini-Mental State Examination score at entry was 21.; Conclusion: This large multicenter trial will address the unanswered question of the long-term safety and effectiveness of alpha-tocopherol, memantine, and their combination in patients with mild-to-moderate AD taking an acetylcholinesterase inhibitor. The results are expected in early 2013.; Published by Elsevier Inc.

Bibtex Citation

@article{Dysken_2014, doi = {10.1016/j.jalz.2013.01.014}, url = {}, year = 2014, month = {jan}, publisher = {Elsevier {BV}}, volume = {10}, number = {1}, pages = {36--44}, author = {Maurice W. Dysken and Peter D. Guarino and Julia E. Vertrees and Sanjay Asthana and Mary Sano and Maria Llorente and Muralidhar Pallaki and Susan Love and Gerard D. Schellenberg and J. Riley McCarten and Julie Malphurs and Susana Prieto and Peijun Chen and David J. Loreck and Sara Carney and George Trapp and Rajbir S. Bakshi and Jacobo E. Mintzer and Judith L. Heidebrink and Ana Vidal-Cardona and Lillian M. Arroyo and Angel R. Cruz and Neil W. Kowall and Mohit P. Chopra and Suzanne Craft and Stephen Thielke and Carolyn L. Turvey and Catherine Woodman and Kimberly A. Monnell and Kimberly Gordon and Julie Tomaska and Govind Vatassery}, title = {Vitamin E and memantine in Alzheimer{textquotesingle}s disease: Clinical trial methods and baseline data}, journal = {Alzheimer{textquotesingle}s {&} Dementia} }


aged, aged, 80 and over, alphatocopherol, alzheimer disease, alzheimer’s disease, antioxidants, cholinesterase inhibitors, double-blind method, drug therapy, excitatory amino acid antagonists, female, humans, longitudinal studies, male, memantine, psychiatric status rating scales, randomized trials, therapeutic use, veterans, vitamin e

Countries of Study


Types of Dementia

Alzheimer’s Disease

Types of Study

Randomised Controlled Trial

Type of Outcomes

Activities of Daily Living, ADLs/IADLs, Cognition

Type of Interventions

Pharmaceutical Interventions

Pharmaceutical Interventions

Anti-Alzheimer medications, e.g.: donezepil, galantamine, rivastigmine, memantime